Abstract

Introduction Coronavirus disease 2019 (COVID-19) and acquired immune deficiency syndrome (AIDS) are two viral diseases for which there are currently no definitive treatments. Nowadays, because of the health system's focus on the COVID-19 epidemic, the control of human immunodeficiency virus (HIV) has received less attention. In this review, we will discuss the characteristics of COVID-19 in HIV-positive patients. Material and Methods Using the PRISMA guideline, the databases of Scopus, PubMed, and Web of Science were searched systematically from January 1, 2019 to February 24, 2021. The following keywords were used: "Human Immunodeficiency Virus," "acquired immune deficiency syndrome," "HIV," "AIDS," "COVID-19," "severe acute respiratory syndrome coronavirus 2," "novel coronavirus," "SARS-CoV-2," "nCoV disease," "SARS2," and "2019-nCoV disease." Results Twenty-one percent of studies were conducted in the USA (n = 13), 16 in China (n = 10), and 13 in Italy (n = 8), respectively. The majority of the patients were men (74.3). Tenofovir disoproxil fumarate was used in 47.4 of patients, emtricitabine in 58.4, and lamivudine in 34.8 to treat HIV. Symptoms of HIV patients with COVID-19 included coughing (81.3), fever (62.8), and dyspnea (60). Hydroxychloroquine (39.34) and azithromycin (36.58) were the common treatment options for COVID-19. The total death rate in HIV-positive patients with COVID-19 was about 9. Conclusion In the current systematic review, we demonstrated that HIV-positive patients co-infected with COVID-19 have high comorbidity of hypertension and diabetes mellitus. HIV/COVID-19 co-infection might have negatively influenced the HIV treatment and diagnosis, which indicates the need to regularly screen HIV patients in the COVID-19 pandemic.